A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma

Donor-derived stem cell memory CAR T cells show enhanced expansion and safety in post-HSCT relapse treatment

This first-in-human study (NCT01087294) investigates donor-derived CD19-CAR T cells for treating B cell malignancies relapsing after allogen

Deep phenotyping of skin tissue remodeling in patients with systemic sclerosis treated with CD19-CAR T cells

Phase I CARLYSLE study: CAR T-cell therapy obe-cel shows favorable safety and clinical benefit in severe refractory lupus

This article reports initial results from the phase I CARLYSLE study evaluating obecabtagene autoleucel (obe-cel), a CD19-targeting CAR T-ce

AI-guided discovery identifies GPNMB as promising CAR T cell target for multiple cancers

Researchers developed an AI-driven framework for discovering CAR T cell therapy targets by integrating single-cell RNA sequencing data from

Dual tumour–myeloid targeting of glioblastoma with GPNMB CAR-T cells

Resetting autoimmune disease with CAR cell therapies